Joensuu H, Fraser J, Wildiers H, et al. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study). SABCS 2017, GS3-04.
Ouderen met gemetastaseerd colorectaal carcinoom zijn wel degelijk te behandelen
jul 2017 | Maag-darm-leveroncologie, Ouderen